NQO1-Dependent Redox Cycling of Idebenone: Effects on Cellular Redox Potential and Energy Levels

Short-chain quinones are described as potent antioxidants and in the case of idebenone have already been under clinical investigation for the treatment of neuromuscular disorders. Due to their analogy to coenzyme Q10 (CoQ10), a long-chain quinone, they are widely regarded as a substitute for CoQ10. However, apart from their antioxidant function, this provides no clear rationale for their use in disorders with normal CoQ10 levels. Using recombinant NAD(P)H:quinone oxidoreductase (NQO) enzymes, we observed that contrary to CoQ10 short-chain quinones such as idebenone are good substrates for both NQO1 and NQO2. Furthermore, the reduction of short-chain quinones by NQOs enabled an antimycin A-sensitive transfer of electrons from cytosolic NAD(P)H to the mitochondrial respiratory chain in both human hepatoma cells (HepG2) and freshly isolated mouse hepatocytes. Consistent with the substrate selectivity of NQOs, both idebenone and CoQ1, but not CoQ10, partially restored cellular ATP levels under conditions of impaired complex I function. The observed cytosolic-mitochondrial shuttling of idebenone and CoQ1 was also associated with reduced lactate production by cybrid cells from mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) patients. Thus, the observed activities separate the effectiveness of short-chain quinones from the related long-chain CoQ10 and provide the rationale for the use of short-chain quinones such as idebenone for the treatment of mitochondrial disorders.

[1]  Mark W. Perlin,et al.  Corrigendum: Automated construction of genetic linkage maps using an expert system (MultiMap): a human genome linkage map , 1994, Nature Genetics.

[2]  S. Dimauro,et al.  Treatment of CoQ10 Deficient Fibroblasts with Ubiquinone, CoQ Analogs, and Vitamin C: Time- and Compound-Dependent Effects , 2010, PloS one.

[3]  G. Lenaz,et al.  Modification of respiratory-chain enzyme activities in brown adipose tissue mitochondria by idebenone (hydroxydecyl-ubiquinone) , 2008, Journal of bioenergetics and biomembranes.

[4]  T. Fujita,et al.  Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs. , 1985, Journal of pharmacobio-dynamics.

[5]  M. Kikuchi,et al.  Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: A long-term follow-up study , 2009, Journal of the Neurological Sciences.

[6]  S. Dixon,et al.  Coenzyme Q1 depletes NAD(P)H and impairs recycling of ascorbate in astrocytes , 2006, Brain Research.

[7]  D. Siegel,et al.  NAD(P)H:Quinone Oxidoreductase Activity Is the Principal Determinant of β-Lapachone Cytotoxicity* , 2000, The Journal of Biological Chemistry.

[8]  G. Ferry,et al.  Quinone reductase 2 substrate specificity and inhibition pharmacology. , 2005, Chemico-biological interactions.

[9]  P. O'Brien.  Molecular mechanisms of quinone cytotoxicity. , 1991, Chemico-biological interactions.

[10]  M. Vrbacký,et al.  Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone. , 2006, Biochemical and biophysical research communications.

[11]  I. Sipes.  Contemporary issues in toxicology , 1988 .

[12]  V. Cardile,et al.  Tolerability and improved protective action of idebenone-loaded pegylated liposomes on ethanol-induced injury in primary cortical astrocytes. , 2004, Journal of pharmaceutical sciences.

[13]  T. C. Jenkins,et al.  Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. , 2000, Cancer research.

[14]  G. Powis,et al.  An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues. , 1995, Cancer research.

[15]  K. Morita,et al.  Idebenone inhibits catecholamine secretion through its blocking action on Ca2+ channels in cultured adrenal chromaffin cells. , 1991, Japanese journal of pharmacology.

[16]  D. J. Long,et al.  NRH:quinone oxidoreductase2 (NQO2). , 2000, Chemico-biological interactions.

[17]  K. Ishii,et al.  Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS , 1996, Neurology.

[18]  Lars Ernster.  [56] DT diaphorase , 1967 .

[19]  L. Landi,et al.  The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Ghelli,et al.  The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. , 1996, Archives of biochemistry and biophysics.

[21]  Caterina Tonon,et al.  Idebenone in Friedreich's ataxia. , 2008, Expert opinion on pharmacotherapy.

[22]  S. Dimauro,et al.  Biochemical analysis of respiratory function in cybrid cell lines harbouring mitochondrial DNA mutations. , 2004, The Biochemical journal.

[23]  A. Munnich,et al.  Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia , 1997, Nature Genetics.

[24]  J. M. Villalba,et al.  Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations , 2010, Expert opinion on investigational drugs.

[25]  Ji Hoon Park,et al.  Pharmacological Stimulation of NADH Oxidation Ameliorates Obesity and Related Phenotypes in Mice , 2009, Diabetes.

[26]  Anbu K. Adikesavan,et al.  In vivo role of NAD(P)H:quinone oxidoreductase 1 in metabolic activation of mitomycin C and bone marrow cytotoxicity. , 2007, Cancer research.

[27]  D. Liebler,et al.  The reduction of alpha-tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha-tocopherolhydroquinone as a cellular antioxidant. , 1997, Molecular pharmacology.

[28]  G. Siciliano,et al.  Long-term treatment with idebenone and riboflavin in a patient with MELAS , 2000, Neurological Sciences.

[29]  T. Yoshida,et al.  CV-2619 protects cultured astrocytes against reperfusion injury via nerve growth factor production. , 2000, European journal of pharmacology.

[30]  A. Jaiswal,et al.  Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. , 1997, Archives of biochemistry and biophysics.

[31]  A. Dinkova-Kostova,et al.  NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. , 2010, Archives of biochemistry and biophysics.

[32]  G M Cohen,et al.  Quinone chemistry and toxicity. , 1992, Toxicology and applied pharmacology.

[33]  G. Lenaz.  A critical appraisal of the mitochondrial coenzyme Q pool , 2001, FEBS letters.

[34]  J. Drewe,et al.  Pharmacokinetic properties and metabolism of idebenone , 2009, Journal of Neurology.

[35]  C. Dawson,et al.  Pulmonary arterial endothelial cells affect the redox status of coenzyme Q0. , 2003, Free radical biology & medicine.

[36]  S. Chapela,et al.  Biochemical study of idebenone effect on mitochondrial metabolism of yeast , 2008, Cell biology international.

[37]  C. Moody,et al.  Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential. , 2008, Organic & biomolecular chemistry.

[38]  T. Wirth,et al.  A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. , 2002, Human molecular genetics.

[39]  M. Berridge,et al.  Evidence for NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated quinone-dependent redox cycling via plasma membrane electron transport: A sensitive cellular assay for NQO1. , 2010, Free radical biology & medicine.

[40]  Anna Lisa Maniero,et al.  Differential effects of mitochondrial Complex I inhibitors on production of reactive oxygen species. , 2009, Biochimica et biophysica acta.

[41]  P. Rustin,et al.  Quinone analogues regulate mitochondrial substrate competitive oxidation. , 2004, Biochemical and biophysical research communications.

[42]  G. Tedeschi,et al.  DT-diaphorase , 1995, The Journal of Biological Chemistry.

[43]  D. Liebler,et al.  The Reduction of α-Tocopherolquinone by Human NAD(P)H:Quinone Oxidoreductase: The Role of α-Tocopherolhydroquinone as a Cellular Antioxidant , 1997 .

[44]  S. Subramony,et al.  Antioxidant use in Friedreich ataxia , 2008, Journal of the Neurological Sciences.

[45]  T. Baillie,et al.  Drug metabolites in safety testing. , 2002, Toxicology and applied pharmacology.

[46]  A. Volterra,et al.  Inhibitory effect of the neuroprotective agent idebenone on arachidonic acid metabolism in astrocytes. , 1999, European journal of pharmacology.

[47]  A. M. James,et al.  Interactions of Mitochondria-targeted and Untargeted Ubiquinones with the Mitochondrial Respiratory Chain and Reactive Oxygen Species , 2005, Journal of Biological Chemistry.

[48]  P. O'Brien,et al.  Coenzyme Q Cytoprotective Mechanisms for Mitochondrial Complex I Cytopathies Involves NAD(P)H: Quinone Oxidoreductase 1(NQO1) , 2002, Free radical research.

[49]  K. Fischbeck,et al.  Mitochondrial abnormalities in spinal and bulbar muscular atrophy , 2008, Human molecular genetics.

[50]  L. Mayer,et al.  Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. , 1985, Biochimica et biophysica acta.

[51]  L. Ernster,et al.  DT diaphorase. I. Purification from the soluble fraction of rat-liver cytoplasm, and properties. , 1962, Biochimica et biophysica acta.

[52]  M. Suno,et al.  Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode of action of the inhibition. , 1984, Biochemical and biophysical research communications.

[53]  M. Suno,et al.  Inhibition of lipid peroxidation by idebenone in brain mitochondria in the presence of succinate. , 1989, Archives of gerontology and geriatrics.